ECT vs Ketamine: What the Evidence Says

This is the comparison at the sharp end of depression care. Electroconvulsive therapy (ECT) is the treatment European guidelines reserve for the severest cases; ketamine is the newer arrival often described, sometimes by people selling it, as the modern replacement. The evidence says something more precise and more interesting than either camp's version. This page lays out what the trials and meta-analyses actually found, where each treatment's real advantages sit, and why the answer differs depending on which patients you ask about. For the wider map of options when treatment has not worked, start with our overview; ketamine's own evidence gets a full review in the ketamine evidence review.

Two treatments, two orders of intervention

ECT is a hospital treatment under general anaesthesia that guidelines reserve for severe depression: when a rapid response is needed or when other treatments have failed (NICE NG222). A brief electrical stimulus induces a controlled seizure under anaesthesia and muscle relaxation; a course typically involves several sessions per week over a few weeks. It carries decades of clinical use, close regulation, and side effects (particularly around memory) that the treating team is obliged to discuss with you. It is often considered after other treatments have failed, but it can also be an early option when a rapid response is essential, including life-threatening depression where someone has stopped eating or drinking, or when a patient prefers it after previous benefit (NICE NG222); treatment failure is not a mandatory prerequisite. For the severest depression it remains one of the most effective treatments medicine has.

Ketamine is a dissociative anaesthetic used off-label for depression, typically as intravenous infusions in a clinic under monitoring. Racemic ketamine, given by intravenous infusion, produces a rapid antidepressant effect that small controlled trials have shown consistently since 2006; the benefit of a single infusion usually fades within one to two weeks, and repeated infusions are used to extend it, with relapse common after stopping (Zarate et al. 2006; Marcantoni et al. 2020). ECT requires a brief general anaesthetic with muscle relaxation; depression-dose ketamine usually does not, but a subanaesthetic dose does not remove medical risk: circulation, oxygenation and level of consciousness are monitored through the session by staff able to manage airway or cardiovascular deterioration, followed by a recovery assessment. Per session, ketamine brings dissociation and a transient rise in blood pressure and heart rate; with repeated or long-term use, real risks documented mainly in heavy exposure: bladder and urinary-tract damage (ketamine uropathy), dependence and, less commonly, liver and bile-duct injury.

What the evidence says, carefully

Where ECT wins

The earlier synthesis is the 2022 systematic review and meta-analysis in JAMA Psychiatry (Rhee et al.), which preceded ELEKT-D: it pooled the randomised trials then available, with mixed and often small populations, and found ECT superior on pooled depression severity outcomes (Rhee et al. 2022). A pooled average of that kind does not show that ECT is superior in every severe presentation, and it does not directly establish the comparison in psychotic depression, where comparative trials are lacking; what it shows is the direction of the evidence before the largest trial reported. A 2026 meta-analysis took a different angle, modelling the time course of response across seven heterogeneous studies with substantial risk of bias (731 participants): ECT showed a steeper average improvement trajectory, but the modelled week-four difference (SMD 0.59, 95% CI -0.26 to 1.43) includes no difference, so faster average improvement is a finding and week-four superiority is not (Nikolin et al. 2026). For hospitalised and severe episodes, guidelines, previous response and clinical judgement carry at least as much weight as these pooled numbers.

Where ketamine holds its ground

The largest single trial tells the other half of the story. ELEKT-D (Anand et al., NEJM 2023) randomised 403 patients with treatment-resistant major depression to ketamine infusions or ECT; 365 received treatment, and in a three-week course ketamine met the prespecified non-inferiority criterion, with response among treated participants of 55.4% versus 41.2% (Anand et al. 2023). Two precisions keep this honest. The trial excluded psychotic depression, precisely where ECT's effect sizes are largest, but it was not an exclusively moderately ill outpatient study: inpatients and very severe nonpsychotic episodes were included, and a secondary analysis explored differences by severity and setting without justifying a rigid selection rule. And non-inferiority on a three-week primary outcome is not equivalence across all patients, treatment courses or long-term outcomes. The question the trial answered: for nonpsychotic treatment-resistant depression, is ketamine a defensible alternative? Its answer was yes. The 2025 network meta-analysis adds that across 35 mostly small RCTs, IV ketamine had significantly higher acceptability (fewer patients dropping out for any reason) than ECT, with efficacy differences not significant and evidence confidence rated very low (Terao et al. 2025).

How both can be true

The apparent contradiction dissolves once populations are kept straight. Meta-analyses that include severe, hospitalised and psychotic cases favour ECT; the flagship trial that excluded them found parity. Reviews on both sides flag the same limits: small samples, unblindable treatments, short follow-up. The fair reading in 2026: *ECT remains the reference standard for the severest depression; ketamine is a credible, less invasive alternative for the nonpsychotic treatment-resistant middle ground, and the choice between them is a clinical judgement about your episode, not a league table.*

Side effects: different currencies

ECT's characteristic cost is cognitive, and it has more than one shape: short-lived confusion right after a treatment, temporary difficulty forming new memories during a course, and retrograde memory loss around the treatment period, which for autobiographical memories can persist; some patients report lasting gaps. The risk varies with technique (electrode placement, pulse width, dosing) and individual factors, modern practice exists largely to reduce it, and the treating team is obliged to discuss it rather than promise complete recovery. ECT also requires repeated brief general anaesthesia, with everything that entails.

Ketamine generally avoids ECT's characteristic cognitive burden in the trial data (cognitive outcomes in ELEKT-D favoured or matched ECT rather than trailing it), but it is not free: attention and awareness are transiently impaired around each session. During an infusion, ketamine commonly causes dissociation, a short-lived rise in blood pressure and heart rate, nausea, dizziness and perceptual changes; these resolve as the drug clears, which is why sessions include monitoring and a recovery period. The risks that deserve real attention come with repeated or long-term use (ketamine uropathy, dependence and, less commonly, liver injury) documented mainly in chronic misuse but relevant to any repeated medical use; the full safety picture is in our ketamine evidence review.

Neither treatment is take-home. Both belong in monitored clinical settings, and after either you do not drive yourself home.

Availability in Europe: opposite doors

ECT runs inside public psychiatry, and you reach it through a psychiatric service, not a website. But availability is not uniform: how many units exist, the referral thresholds and the waits differ between countries and regions, so an equivalent ECT pathway cannot be assumed everywhere.

Ketamine for depression mostly runs outside that system. It is used off-label almost everywhere in Europe, largely in private clinics; public funding for IV ketamine remains uncommon. Norway's August 2025 decision is the clearest exception, and a conditional one: public specialist services only, written off-label consent, registry or study follow-up, after insufficient effect of other authorised treatments, with re-evaluation by end of 2028 (Nye metoder); France's March 2026 compassionate framework is narrower still. Authorisation, reimbursement and an actually available service are three different things, and each claim here links its national policy source. The approved, reimbursable relative is esketamine nasal spray (Spravato): a different product with its own evidence review and practical comparison. Where private ketamine is the realistic route, our directory lists verified clinics and our cost guide the published prices; the eligibility check sorts out which doors exist in your country.

After the acute course, and before any booking

Improvement after an acute course does not guarantee sustained remission, whichever treatment produced it. After ECT, the conversation covers continuation treatment: medication, psychological treatment or, in some services, maintenance ECT. After ketamine, continuation needs individual review, because long-term schedules and their evidence are less established; symptom monitoring, regular benefit-and-risk review and a plan for relapse or non-response belong in the treatment plan from the start. And one safety line applies to both: rapid reduction in depressive symptoms does not establish protection against suicide. Acute suicidal risk, psychotic symptoms, inability to maintain nutrition or severe deterioration require urgent specialist assessment, and an outpatient ketamine service is not a substitute for that level of care.

Practically, the choice is also about logistics and consent: ECT means repeated anaesthetic assessments, escorts and recovery time; ketamine means repeated monitored sessions with transport home each time (and for esketamine, no driving until the next day after restful sleep). Compare whole care pathways and total course costs, not the price or length of a single procedure, and expect a shared decision with the treating team rather than a consumer-style winner.

Frequently asked questions

Is ketamine replacing ECT?

No. Trial activity and clinic growth are on ketamine's side, but the comparative evidence has not displaced ECT for severe depression: the earlier pooled analysis favoured ECT, and guidelines keep it available for exactly the severe, urgent cases where it is strongest, including as an early option when speed is essential. What ketamine has done is widen the middle ground: for nonpsychotic treatment-resistant depression, ELEKT-D showed it is a defensible alternative.

Which is safer?

They spend risk in different currencies, so "safer" has no single answer. ECT's burden is cognitive (memory effects) plus repeated general anaesthesia, inside a heavily regulated hospital pathway. Ketamine avoids both but brings dissociation and blood-pressure rises per session and bladder-damage and dependence risks with repeated use. Individual factors (cardiovascular status, psychiatric history, anaesthesia risk) can tip the balance either way, which is one more reason this is a specialist decision.

Can I choose ketamine to avoid ECT's memory effects?

That preference is legitimate and worth voicing: acceptability is precisely where ketamine scored better in the network meta-analysis. But whether it is clinically sensible depends on your episode: with psychotic features, catatonia or life-threatening severity, steering away from ECT can mean steering away from the treatment most likely to work. Put the preference on the table with the psychiatric team rather than deciding alone.

Does anything here apply to esketamine (Spravato)?

Only partly. The head-to-head trials above used racemic IV ketamine, not the nasal spray. Esketamine has its own regulatory trial programme and its own licensed regimen: treatment-resistant depression together with an oral SSRI or SNRI, and a separate short-term indication, with an oral antidepressant, for rapid reduction of depressive symptoms in a psychiatric emergency. Neither the licence nor ELEKT-D establishes the effectiveness of every ketamine route or of any particular psychotherapy package around it. See the esketamine evidence review.

How do I even get assessed for either?

Through psychiatry, with your treatment record in hand. ECT is proposed by a treating psychiatric team, usually at the severe end of an episode. For ketamine, a legitimate clinic will require a psychiatric assessment and screening rather than selling you a course; what that screening should cover is in how to prepare for ketamine therapy. If you are at the two-failed-antidepressants stage and mapping options, start here.

Sources

1. Rhee et al. (2022), JAMA Psychiatry — efficacy and safety of ketamine vs ECT: systematic review and meta-analysis
2. Anand et al. (2023), New England Journal of Medicine — ELEKT-D: ketamine versus ECT for nonpsychotic treatment-resistant major depression
3. Nikolin et al. (2026), Translational Psychiatry — time-course meta-analysis of ECT vs ketamine for depression
4. Terao et al. (2025), PCN Reports — network meta-analysis of IV ketamine, rTMS and ECT in treatment-resistant depression
5. NICE NG222 — depression in adults: treatment and management
6. Zarate et al. (2006), Archives of General Psychiatry — single-infusion ketamine in treatment-resistant depression
7. Marcantoni et al. (2020), Journal of Affective Disorders — meta-analysis of IV ketamine for treatment-resistant depression
8. British Association of Urological Surgeons (2024), BJU International — consensus on ketamine uropathy
9. Nye metoder / Beslutningsforum (2025) — decision on IV ketamine for treatment-resistant depression
10. ELEKT-D secondary analysis — outcomes by severity and treatment setting
11. Swainson et al. (2021), CANMAT — recommendations on ketamine use in depression
12. RCPsych — ECT patient information (cognitive effects, consent)
13. EMA — Spravato (esketamine) product information

This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. ECT and ketamine decisions are specialist decisions made with a psychiatric team that knows your history. If you are in crisis, contact your local emergency number (112 in the EU) or a crisis line immediately.